To further strengthen the anti-tumor activity, STO-1 treatment evokes intra-tumor recruitment of activated and tumoricidal NK cells and CD8+ cytotoxic T-cells (Figure 6) [4,5,6,46,64]. Here, NSD1 is linked to neoplasm.